Expanding the use of magnetic resonance in the assessment of tumor response to therapy: Workshop report

Cancer Research

Volumn 65, Issue 16, 2005, Pages 7041-7044

  Evelhoch, Jeffrey ^b   Garwood, Michael ^c   Vigneron, Daniel ^d   Knopp, Michael ^e   Sullivan, Daniel ^a   Menkens, Anne ^a   Clarke, Laurence ^a   Liu, Guoying ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN;

BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONFERENCE PAPER; CONTRAST ENHANCEMENT; HUMAN; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; TECHNIQUE; TREATMENT OUTCOME;

HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASMS;

EID: 23844456531     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0674     Document Type: Conference Paper

References (18)

1. Leach MO, Brindle KM, Evelhoch JL, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005;92:1599-610.
2. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases. J Clin Oncol 2003;21:3955-64.
3. Meisamy S, Bolan PJ, Baker EH, et al. Predicting response to neoadjuvant chemotherapy of locally advanced breast cancer with in vivo 1H MRS: a pilot study at 4 Tesla. Radiology 2004;233:424-31.
4. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrastenhanced T(1)-weighted MRI of a diffusible tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-32.
5. Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 2003;17:509-20.
6. Costouros NG, Lorang D, Zhang Y, et al. Microarray gene expression analysis of murine tumor heterogeneity defined by dynamic contrast-enhanced MRI. Mol Imaging 2002;1:301-8.
7. Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831-42.
8. Rustin GJ, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003;21:2815-22.
9. McShane T, Ashton E, Jackson E, et al. Dynamic contrast-enhanced MRI (DCE-MRI) evaluation of the effects of the VEGF/PDGF receptor tyrosine kinase inhibitor AG-013736 on tumor vasculature in a phase I clinical trial. 12th Meeting International Society for Magnetic Resonance in Medicine, Kyoto, Japan; 2004 May.
10. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999;59:80-4.
11. Herminghaus S, Pilatus U, Moller-Hartmann W, et al. Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors. NMR Biomed 2002;15:385-92.
12. Ruiz-Cabello J, Cohen JS, Phospholipid metabolites as indicators of cancer cell function. NMR Biomed 1992;5:226-33.
13. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. A combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging 2002;16:451-63.
14. Nelson SJ. Multivoxel magnetic resonance spectroscopy of brain tumors. Mol Cancer Ther 2003;2:497-507.
15. Nelson SJ. Magnetic resonance spectroscopic imaging. Evaluating responses to therapy for gliomas. IEEE Eng Med Biol Mag 2004;23:30-9.
16. Strecker R, Scheffler K, Buchert M, Mross K, Drevs J, Hennig J. DCE-MRI in clinical trials: data acquisition techniques and analysis methods. Int J Clin Pharmacol Ther 2003;41:603-5.
17. Evelhoch J. Consensus recommendations for acquisition of dynamic contrasted-enhanced MRI data in oncology. In; Jackson A, Buckley D, Parker GJM. editors. Dynamic contrast-enhanced magnetic resonance imaging in oncology. Berlin: A Springer; 2005. p. 109-14.
18. Collins JM. Functional imaging in phase I studies: decorations or decision making? J Clin Oncol 2003;21:2807-9.